The approval of crizotinib was accompanied the simultaneous approval of the Vysis (Abbott Molecular) break-apart fluorescence in situ hybridization (FISH) companion diagnostics (CDx) assay by the US Food and Drug Administration (FDA) for the detection of ALK rearrangement in NSCLC. The gene discussed is ALK; the disease is non-small cell lung carcinoma.